Tocilizumab was suggested to prevent a cytokine storm by blocking IL-6R and disrupting the IL-6 signaling pathway, however, because MAS is attributed to various cytokines, including IL-1 and IL-18, inhibition of IL-6 might not be sufficient to prevent MAS [1–3]. The gene discussed is IL18; the disease is macrophage activation syndrome.